Enlivex Therapeutics RDO Ltd.
Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages for the treatment of inflammatory diseases. The company aims to harness the natural healing power of macrophages to treat various inflammatory conditions, both acute and chronic, with a focus on diseases like sepsis and osteoarthritis. Enlivex's innovative approach involves macrophage modulation through apoptotic cell therapy, which has demonstrated a favorable safety profile in clinical trials and targets a substantial unmet medical need in inflammatory disease markets.
Industries
Nr. of Employees
small (1-50)
Enlivex Therapeutics RDO Ltd.
Weizmann Science Park, 14 Einstein St., Ness Ziona, 7403618, Israel
Patents
Combination immune therapy and cytokine control therapy for cancer treatment
US-11497767-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11318163-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11304976-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11000548-B2
View DetailsTherapeutic apoptotic cell preparations, method for producing same and uses thereof
US-10927343-B2
View Details
Combination immune therapy and cytokine control therapy for cancer treatment
US-11497767-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11318163-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11304976-B2
View DetailsCombination immune therapy and cytokine control therapy for cancer treatment
US-11000548-B2
View DetailsTherapeutic apoptotic cell preparations, method for producing same and uses thereof
US-10927343-B2
View DetailsProducts
Off‑the‑shelf apoptotic allogeneic cell therapy for macrophage homeostasis
A frozen, donor‑derived mononuclear cell therapy induced into a stable apoptotic state and formulated as ready‑to‑use doses intended to restore macrophage homeostasis and modulate inflammatory responses.
Off‑the‑shelf apoptotic allogeneic cell therapy for macrophage homeostasis
A frozen, donor‑derived mononuclear cell therapy induced into a stable apoptotic state and formulated as ready‑to‑use doses intended to restore macrophage homeostasis and modulate inflammatory responses.
Services
Design and conduct of Phase I/II/IIb clinical studies including randomized, double‑blind, placebo‑controlled multi‑center trials and investigator‑initiated studies.
Centralized production, cryopreservation and distribution of ready‑to‑use frozen cell therapy doses for clinical administration.
Execution of animal toxicology studies and development of in‑vitro potency and biological activity assays to support product characterization and IND/clinical programs.
Policy framework and case evaluation process to consider access to investigational therapies for patients outside of clinical trials under defined criteria.
Design and conduct of Phase I/II/IIb clinical studies including randomized, double‑blind, placebo‑controlled multi‑center trials and investigator‑initiated studies.
Centralized production, cryopreservation and distribution of ready‑to‑use frozen cell therapy doses for clinical administration.
Execution of animal toxicology studies and development of in‑vitro potency and biological activity assays to support product characterization and IND/clinical programs.
Policy framework and case evaluation process to consider access to investigational therapies for patients outside of clinical trials under defined criteria.
Expertise Areas
- Macrophage reprogramming and immunomodulation
- Cell therapy development (allogeneic apoptotic cell products)
- Cryopreserved biologics formulation and supply
- Clinical trial design and operational execution
Key Technologies
- Apoptotic cell‑based therapy
- Allogeneic peripheral blood mononuclear cell processing
- Apoptosis induction and stabilization methods
- Cryogenic cell preservation and frozen dose formulation
News & Updates
Enlivex announced it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress, highlighting clinical data related to osteoarthritis.
Enlivex will highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases at the Israeli BioMed 2025 Conference.
Enlivex announced that it will showcase Allocetra™'s potential in osteoarthritis at the OARSI 2025 World Congress, emphasizing its mechanism targeting immune imbalance in joint disease.
A study published in Pharmaceutics 2024 demonstrating the safety of Allocetra-OTS in animal models.
A publication in Frontiers in Immunology 2023 discussing the use of apoptotic cells in COVID-19 related respiratory distress.
A poster presented at ISCT 2023 highlighting the company's approach to macrophage reprogramming.
Enlivex announced it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress, highlighting clinical data related to osteoarthritis.
Enlivex will highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases at the Israeli BioMed 2025 Conference.
Enlivex announced that it will showcase Allocetra™'s potential in osteoarthritis at the OARSI 2025 World Congress, emphasizing its mechanism targeting immune imbalance in joint disease.
A study published in Pharmaceutics 2024 demonstrating the safety of Allocetra-OTS in animal models.
A publication in Frontiers in Immunology 2023 discussing the use of apoptotic cells in COVID-19 related respiratory distress.
A poster presented at ISCT 2023 highlighting the company's approach to macrophage reprogramming.